The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells

Biomaterials

Volumn 32, Issue 30, 2011, Pages 7641-7650

  Ren, Jun Lin ^a   Meng, Yan Ling ^a   Hu, Bin ^b   Jia, Lin Tao ^a   Zhang, Rui ^a   Xu, Yan Ming ^a   Xie, Qiao Sheng ^a   Zhang, Ying Qi ^a   Jin, Bo Quan ^a   Chen, Si Yi ^c   Wang, Tao ^a   Yang, An Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b The 305 Hospital of Chinese PLA   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Apoptosis; Gastric cancer; HER2; Translocation

Indexed keywords

ANTI-TUMOR ACTIVITIES; C-TERMINAL FRAGMENTS; CANCER CELLS; CONSTITUTIVELY ACTIVES; CYTOTOXIC; DIPHTHERIA TOXIN; ENDOPLASMIC RETICULUM; ENDOSOMES; GASTRIC CANCER CELLS; GASTRIC CANCERS; GENETICALLY MODIFIED; HER2; NUDE MICE; PSEUDOMONAS EXOTOXIN A; RECEPTOR-MEDIATED ENDOCYTOSIS; RECOMBINANT PROTEIN; SINGLE-CHAIN ANTIBODIES; TRANSLOCATION; TRANSLOCATION PATHWAY; TUMOR GROWTH; TUMOR MODELS;

CELL DEATH; CYTOTOXICITY; MAMMALS; MOLECULAR BIOLOGY; MONOCLONAL ANTIBODIES; PROTEINS; TUMORS;

DISEASES;

DIPHTHERIA TOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FURIN; LAMIN A; LIPOSOME; RECOMBINANT CASPASE 6; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN E23SFV; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL TRANSPORT; CYTOTOXICITY; DOWN REGULATION; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENDOPLASMIC RETICULUM; ENDOSOME; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; TRANS GOLGI NETWORK; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTIBODIES; APOPTOSIS; CASPASE 6; CELL LINE, TUMOR; CYTOSOL; DIPHTHERIA TOXIN; ENDOSOMES; FURIN; HUMANS; LAMIN TYPE A; LIPOSOMES; MICE; MICE, NUDE; PROTEIN TRANSPORT; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; STOMACH NEOPLASMS;

ANIMALIA; MUS MUSCULUS; PISUM SATIVUM; PSEUDOMONAS EXOTOXIN;

EID: 80051547073     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.06.071     Document Type: Article

References (40)

1. Gown A.M. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21:S8-S15.
2. Bunn P.A., Helfrich B., Soriano A.F., Franklin W.A., Varella-Garcia M., Hirsch F.R., et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001, 7(10):3239-3250.
3. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244(4905):707-712.
4. Yonemura Y., Ninomiya I., Yamaguchi A., Fushida S., Kimura H., Ohoyama S., et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991, 51(3):1034-1038.
5. Nakajima M., Sawada H., Yamada Y., Watanabe A., Tatsumi M., Yamashita J., et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85(9):1894-1902.
6. Gravalos C., Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008, 19(9):1523-1529.
7. Tanner M., Hollmén M., Junttila T.T., Kapanen A.I., Tommola S., Soini Y., et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005, 16(2):273-278.
8. Okines A.F., Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer 2010, 46(11):1949-1959.
9. Hofmann M., Stoss O., Shi D., Büttner R., van de Vijver M., Kim W., et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52(7):797-805.
10. Fischer U., Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005, 57(2):187-215.
11. Jia L.T., Zhang L.H., Yu C.J., Zhao J., Xu Y.M., Gui J.H., et al. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 2003, 63(12):3257-3262.
12. Zhao J., Zhang L.H., Jia L.T., Zhang L., Xu Y.M., Wang Z., et al. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem 2004, 279(20):21343-21348.
13. Xu Y.M., Wang L.F., Jia L.T., Qiu X.C., Zhao J., Yu C.J., et al. A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol 2004, 173(1):61-67.
14. Yu C.J., Jia L.T., Meng Y.L., Zhao J., Zhang Y., Qiu X.C., et al. Selective proapoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2. Gene Ther 2006, 13(4):313-320.
15. Qiu X.C., Xu Y.M., Wang F., Fan Q.Y., Wang L.F., Ma B.A., et al. Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth. Mol Cancer Ther 2008, 7(7):1890-1899.
16. Wang T., Zhao J., Ren J.L., Zhang L., Wen W.H., Zhang R., et al. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res 2007, 67(24):11830-11839.
17. McKeage K., Perry C.M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002, 62(1):209-243.
18. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
19. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18(6):977-984.
20. Mayer I.A. Treatment of HER2-positive metastatic breast cancer following initial progression. Clin Breast Cancer 2009, 2(9 Suppl):S50-S57.
21. Orth K., Chinnaiyan A.M., Garg M., Froelich C.J., Dixit V.M. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 1996, 271(28):16443-16446.
22. Ruchaud S., Korfali N., Villa P., Kottke T.J., Dingwall C., Kaufmann S.H., et al. Caspase-6 gene disruption reveals a requirement for lamin A cleavage in apoptotic chromatin condensation. EMBO J 2002, 21(8):1967-1977.
23. Falnes P.O., Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol 2000, 12(4):407-413.
24. Pastan I., Hassan R., Fitzgerald D.J., Kreitman R.J. Immunotoxin therapy of cancer. Nat Rev Cancer 2006, 6(7):559-565.
25. Wanyiri J.W., O'Connor R., Allison G., Kim K., Kane A., Qiu J., et al. Proteolytic processing of the cryptosporidium glycoprotein gp40/15 by human furin and by a parasite-derived furin-like protease activity. Infect Immun 2007, 75(1):184-192.
26. Asanuma H., Torigoe T., Kamiguchi K., Hirohashi Y., Ohmura T., Hirata K., et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res 2005, 65(23):11018-11025.
27. Kim S.Y., Kim H.P., Kim Y.J., Oh do Y., Im S.A., Lee D., et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 2008, 32(1):89-95.
28. Yakes F.M., Chinratanalab W., Ritter C.A., King W., Seelig S., Arteaga C.L. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002, 62(14):4132-4141.
29. Lee S., Yang W., Lan K.H., Sellappan S., Klos K., Hortobagyi G., et al. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 2002, 62(20):5703-5710.
30. Benbrook D.M. An ELISA method for detection of human antibodies to an immunotoxin. J Pharmacol Toxicol Methods 2002, 47(3):169-175.
31. Posey J.A., Khazaeli M.B., Bookman M.A., Nowrouzi A., Grizzle W.E., Thornton J., et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002, 8(10):3092-3099.
32. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002, 3(10):753-766.
33. Komata T., Kondo Y., Kanzawa T., Hirohata S., Koga S., Sumiyoshi H., et al. Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res 2001, 61(15):5796-5802.
34. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24(14):2137-2150.
35. Nahta R., Yu D., Hung M.C., Hortobagyi G.N., Esteva F.J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006, 3(5):269-280.
36. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17(9):2639-2648.
37. Rüschoff J., Dietel M., Baretton G., Arbogast S., Walch A., Monges G., et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010, 457(3):299-307.
38. Montemurro F., Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 2005, 6(1):77-80.
39. Vogel C.L., Cobleigh M.A., Tripathy D., Gutheil J.C., Harris L.N., Fehrenbacher L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20(3):719-726.
40. Spector N.L., Blackwell K.L. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2009, 27(34):5838-5847.